Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs (Nasdaq: VRAX) entered a definitive agreement for the immediate exercise of preferred investment options to buy up to 548,000 ordinary shares at a reduced exercise price of $6.00 per share, raising an expected $3.3 million in gross proceeds.

Rhea-AI Summary

Virax Biolabs (Nasdaq: VRAX) entered a definitive agreement for the immediate exercise of preferred investment options to buy up to 548,000 ordinary shares at a reduced exercise price of $6.00 per share, raising an expected $3.3 million in gross proceeds.

According to Virax, investors exercising these options will receive new unregistered Series A and short-term Series B preferred investment options (New Warrants) covering up to 1,644,000 additional ordinary shares at $6.00 per share. Closing is expected around July 10, 2026, with net proceeds used for working capital and general corporate purposes.

Positive

• Immediate exercise expected to generate approximately $3.3 million in gross proceeds
• Reduced exercise price of $6.00 per share may encourage warrant exercise
• Issuance of New Warrants covering up to 1,644,000 ordinary shares at $6.00
• Net proceeds intended for working capital and general corporate purposes
• Offering expected to close around July 10, 2026, subject to conditions

Negative

• Exercise and New Warrants involve up to 2,192,000 ordinary shares, increasing potential share count
• New Series A and Series B Preferred Investment Options are unregistered and issued via private placement
• Series A and Series B exercises depend on shareholder approval for an authorized share increase
• Original preferred investment options’ exercise price reduced from $10.00 to $6.00 per share

Argus Jul 9 session 185 alerts

+100.00% close to close 378.3x rel. volume Open Argus

Details

Market move: VRAX +100.00% in the Jul 9 session. preferred investment option exercise

+280.4% Peak in 2 hr 29 min

$2.42M Mkt Cap at Peak Alert

On Jul 9, the day this news came out, VRAX closed 100.00% above the previous close. Argus tracked a peak move of +280.4% during that session. Our momentum scanner recorded 185 alerts for this stock that day. Relative volume reached 378.3x the daily average during tracking.

Data tracked by StockTitan Argus for the Jul 9 session.

Key Figures

Ordinary shares exercised: 548,000 shares Original exercise price: $10.00 per share Reduced exercise price: $6.00 per share +5 more

Ordinary shares exercised

548,000 shares

Immediate exercise of preferred investment options

Original exercise price

$10.00 per share

Preferred investment options issued Oct 2023 and Dec 2025

Reduced exercise price

$6.00 per share

Repriced preferred investment options for immediate exercise

Gross proceeds

$3.3 million

Expected proceeds to company before fees from option exercises

Series A new warrants

548,000 shares

New unregistered Series A Preferred Investment Options

Series B new warrants

1,096,000 shares

New short-term unregistered Series B Preferred Investment Options

New warrant exercise price

$6.00 per share

Exercise price for both Series A and Series B New Warrants

Expected closing date

July 10, 2026

Expected closing of offering, subject to customary conditions

Historical Context

4 past events · Latest: Jun 24

4 events

1. Jun 24

   share consolidation

   24h Move

   -14.8%

   1-for-25 share consolidation to address Nasdaq minimum bid price requirements.

2. May 26

   clinical data update

   24h Move

   -18.2%

   Positive early ViraxImmune pilot data in Long COVID and related PAIS.

3. Apr 14

   strategy update

   24h Move

   -11.1%

   CEO letter outlining strategy, milestones and cash position versus market cap.

4. Mar 31

   regulatory certification

   24h Move

   +35.3%

   ISO 13485 and ISO 9001 quality certifications supporting regulated IVD development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form f-3, placement agent, private placement, registration statement

4 terms

form f-3 regulatory

"registered pursuant to effective registration statements on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

placement agent financial

"H.C. Wainwright & Co. is acting as the exclusive placement agent"

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

private placement financial

"were offered in a private placement pursuant to an applicable exemption"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

registration statement regulatory

"file a registration statement with the SEC covering the resale"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share.  The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos. 333-292241 and 333-275893). The gross proceeds to the Company from the exercise of the preferred investment options are expected to be approximately $3.3 million, prior to deducting placement agent fees and estimated offering expenses.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the preferred investment options for cash, the Company will issue new unregistered Series A Ordinary Share Preferred Investment Options (the "Series A Preferred Investment Option") to purchase up to an aggregate of 548,000 Ordinary Shares and new short-term unregistered Series B Ordinary Share Preferred Investment Options (the "Series B Preferred Investment Option," together with the Series A Preferred Investment Option, the "New Warrants") to purchase up to an aggregate of 1,096,000 Ordinary Shares. The New Warrants will have an exercise price of $6.00 per Ordinary Share. The Series A Preferred Investment Option will be exercisable on or after the date of the approval by the shareholders of the Company of the increase in authorized Ordinary Shares of the Company (the "Authorized Share Increase") and will expire five years following the later of the effective date of the resale registration statement registering the Ordinary Shares issuable upon exercise of the Series A Preferred Investment Option (the "Effective Date") and the Authorized Share Increase, and the short-term Series B Preferred Investment Option will be exercisable on or after the date of the Authorized Share Increase and will expire eighteen months following the later of the Effective Date and the Authorized Share Increase.

The offering is expected to close on or about July 10, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the Ordinary Shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the Ordinary Shares issuable upon exercise of the New Warrants.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune™, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.

For more information, please visit www.viraxbiolabs.com 

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: the completion of the offering; satisfaction of the closing conditions; use of proceeds from the offering; and the receipt of shareholder approval of the Authorized Share Increase; our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2026. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-exercise-of-preferred-investment-options-for-3-3-million-gross-proceeds-302822153.html

SOURCE Virax BioLabs Group Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Virax Biolabs (NASDAQ: VRAX) announce on July 9, 2026?

Virax Biolabs announced a definitive agreement for immediate exercise of certain preferred investment options, raising about $3.3 million in gross proceeds. According to Virax, the deal includes issuing new Series A and Series B preferred investment options for additional ordinary shares at $6.00 per share.

How much capital will Virax Biolabs (VRAX) raise from the preferred investment option exercise?

Virax Biolabs expects to raise approximately $3.3 million in gross proceeds from the immediate exercise of preferred investment options. According to Virax, this amount is before deducting placement agent fees and estimated offering expenses, with net proceeds earmarked for working capital and general corporate purposes.

What are the terms of the new Series A and Series B preferred investment options for Virax (VRAX)?

The new Series A and Series B preferred investment options allow purchases of up to 1,644,000 ordinary shares at $6.00 per share. According to Virax, Series A will be exercisable for five years after specified dates, while short-term Series B will be exercisable for eighteen months.

When will the Virax Biolabs (VRAX) preferred investment option transaction close?

The preferred investment option exercise and related private placement are expected to close on or about July 10, 2026. According to Virax, the closing remains subject to satisfaction of customary closing conditions associated with this type of capital markets transaction.

How will Virax Biolabs use the proceeds from the $3.3 million preferred option exercise?

Virax Biolabs plans to use the net proceeds from the preferred investment option exercise as working capital and for general corporate purposes. According to Virax, this capital raise supports ongoing operational needs rather than being earmarked for a specific acquisition or project.

Are the new Virax Biolabs Series A and B warrants registered with the SEC?

The new Series A and Series B preferred investment options are being issued in a private placement and are currently unregistered. According to Virax, the company has agreed to file a registration statement covering resale of the ordinary shares issuable upon exercise of these New Warrants.

What is the exercise price change for Virax Biolabs (VRAX) preferred investment options?

Certain outstanding preferred investment options originally had a $10.00 per share exercise price, now reduced to $6.00 per share. According to Virax, this revised pricing applies to options covering up to 548,000 ordinary shares that are being exercised for cash under the new agreement.